Elekta AB (publ) (EKTA-B)
Stockholm Exchange · Sweden · prices in SEK · close of 23 Oct 2026
Key indicators
| Last close | SEK 57.60 |
|---|---|
| 52-week range | 41.86 – 66.70 |
| Return, 1 month / 3 months | +10.8% / +29.0% |
| Return, 1 year / 3 years | +18.1% / −14.8% |
| Trend | Uptrend |
| RSI (14) | 70 |
| Volatility (1 year) | 40.4% |
| Worst drawdown (1 year) | -26.9% |
| Average daily value traded | 65.01M SEK |
| Dividend yield | 4.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Elekta AB is a Swedish medical technology company that develops equipment and software for cancer treatment and brain surgery. Its products include radiotherapy and radiosurgery systems, such as the Leksell Gamma Knife and linear accelerators, along with brachytherapy tools and neurosurgery solutions. Hospitals and cancer treatment centres around the world use its systems to plan and deliver precise radiation treatment. The company is based in Stockholm, Sweden.
The shares are listed on the Stockholm Exchange in Sweden under the code EKTA-B, and the price on this page is in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Elekta AB (publ) (EKTA-B) trades on the Stockholm Exchange in Sweden. It last closed at SEK 57.60 on 23 October 2026.
Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 122 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 18.1% and over the last three months it rose 29.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 74 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.6% | ||
| From 52-week high | -8.9% | ||
| Momentum | 77 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 29.0% | ||
| 6-month return | 5.8% | ||
| 12-month return, skipping the last month | 6.7% | ||
| Stability (higher is calmer) | 69 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 40.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.9% | ||
| Liquidity | 93 · Strong | Trades actively. | |
| Average daily value traded | 65.01M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 66 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.2% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +1.0% |
|---|---|
| 1 month | +10.8% |
| 3 months | +29.0% |
| 6 months | +5.8% |
| 1 year | +18.1% |
| 3 years | −14.8% |
| 5 years | −30.0% |
Signals
| 50-day / 200-day average | 53.02 / 53.05 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.43 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 4 Mar 2027 | SEK 1.2000 |
| 4 Sep 2026 | SEK 1.2000 |
| 5 Mar 2026 | SEK 1.2000 |
| 5 Sep 2025 | SEK 1.2000 |
| 6 Mar 2025 | SEK 1.2000 |
| 6 Sep 2024 | SEK 1.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.